It's never too early to beat your low-density lipoprotein cholesterol.
作者信息
Bergerot Cyrille, Angoulvant Denis, Lemesle Gilles, Barone-Rochette Gilles, Mewton Nathan, Mach François
机构信息
Service des Explorations Fonctionnelles Cardiovasculaires, Hôpital Louis Pradel, Hospices Civils de Lyon, 69500 Bron, France; Hôpital Cardiovasculaire Louis Pradel, Hospices Civils de Lyon, Inserm UMR 1060 CarMeN, Université Claude Bernard Lyon 1, 69500 Bron, France.
Cardiology Department and EA4245 T2i, Faculté de Médecine, Tours University Hospital, Tours University, 37000 Tours, France.
出版信息
Arch Cardiovasc Dis. 2021 Jan;114(1):1-3. doi: 10.1016/j.acvd.2021.01.001. Epub 2021 Jan 25.
PMID:33509745
Abstract
摘要
相似文献
1
It's never too early to beat your low-density lipoprotein cholesterol.降低低密度脂蛋白胆固醇，越早越好。
Arch Cardiovasc Dis. 2021 Jan;114(1):1-3. doi: 10.1016/j.acvd.2021.01.001. Epub 2021 Jan 25.
2
AHA/ACC/Multisociety Cholesterol Guidelines: highlights.美国心脏协会/美国心脏病学会/多学会胆固醇指南：要点
Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719881579. doi: 10.1177/1753944719881579.
3
Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review.基线低密度脂蛋白胆固醇预测降脂治疗心血管获益程度：综述。
Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):47-54. doi: 10.1093/ehjcvp/pvy038.
4
Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?前蛋白转化酶枯草溶菌素9型（PCSK9）抑制剂与心血管风险：对傅里叶试验的进一步分析是否提示降脂治疗靶点的变化？
High Blood Press Cardiovasc Prev. 2018 Mar;25(1):5-7. doi: 10.1007/s40292-017-0244-x. Epub 2018 Jan 5.
5
Gaps in Dyslipidemia Care Among Working-Aged Individuals With Employer-Sponsored Health Care.工作年龄段人群中存在血脂异常管理差距，他们拥有雇主提供的医疗保险。
J Am Heart Assoc. 2020 May 5;9(9):e015807. doi: 10.1161/JAHA.119.015807. Epub 2020 Apr 22.
6
Suboptimal achievement of low-density lipoprotein cholesterol targets in French patients with coronary heart disease. Contemporary data from the DYSIS II ACS/CHD study.法国冠心病患者低密度脂蛋白胆固醇目标未达最佳水平。来自DYSIS II ACS/CHD研究的当代数据。
Arch Cardiovasc Dis. 2017 Mar;110(3):167-178. doi: 10.1016/j.acvd.2016.11.004. Epub 2017 Feb 13.
7
Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.降脂治疗与急性冠状动脉综合征后 LDL-C 目标达标：一项丹麦基于人群的队列研究。
BMC Cardiovasc Disord. 2020 Jul 13;20(1):336. doi: 10.1186/s12872-020-01616-9.
8
Do Risk-Enhancing Factors Enhance Risk Estimation?风险增强因素会提高风险评估吗？
Circ Cardiovasc Qual Outcomes. 2019 Nov;12(11):e006078. doi: 10.1161/CIRCOUTCOMES.119.006078. Epub 2019 Nov 13.
9
Counterpoint: Low-Density Lipoprotein Cholesterol Targets Are Not Needed in Lipid Treatment Guidelines.反驳观点：血脂治疗指南中不需要低密度脂蛋白胆固醇目标值。
Arterioscler Thromb Vasc Biol. 2016 Apr;36(4):586-90. doi: 10.1161/ATVBAHA.116.306887. Epub 2016 Mar 17.
10
Achievement of low-density lipoprotein cholesterol goals in 18 countries outside Western Europe: The International ChoLesterol management Practice Study (ICLPS).18 个西欧以外国家的低密度脂蛋白胆固醇目标达标情况：国际胆固醇管理实践研究（ICLPS）。
Eur J Prev Cardiol. 2018 Jul;25(10):1087-1094. doi: 10.1177/2047487318777079. Epub 2018 May 17.
Zotero 插件